HC Wainwright Reiterates “Neutral” Rating for Predictive Oncology (NASDAQ:POAI)

Predictive Oncology (NASDAQ:POAI)‘s stock had its “neutral” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports.

Predictive Oncology Stock Down 8.6 %

Shares of NASDAQ POAI opened at $0.74 on Friday. The company has a market capitalization of $4.94 million, a PE ratio of -0.24 and a beta of 1.14. The firm has a fifty day simple moving average of $0.76 and a 200 day simple moving average of $1.07. Predictive Oncology has a twelve month low of $0.55 and a twelve month high of $3.76.

Predictive Oncology (NASDAQ:POAI) last announced its earnings results on Tuesday, August 13th. The medical instruments supplier reported ($0.68) EPS for the quarter. The business had revenue of $0.28 million for the quarter. Predictive Oncology had a negative net margin of 1,012.32% and a negative return on equity of 286.30%. As a group, equities analysts expect that Predictive Oncology will post -2.03 earnings per share for the current fiscal year.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.